

## Vigmed's launch of CLiP® Ven expected to take place in May 2014

For further information  
contact:

Chairman of the Board  
Lennart Holm  
+46 70-630 8562 or

CEO  
Finn Ketler  
+46 42 600 5311

**A product launch in May means a delay of two months compared to what was previously been communicated to the market.**

Preparations for full scale production of the CLiP® Ven product have progressed, however difficulties in the fine-tuning of the assembly lines have resulted in a launch delay. On the positive side, the company has now reached a point where it believes that the production ramp-up of the high-tech assembly lines at the new HMD plant in Faridabad, India, can soon start.

In a comment regarding the delay Finn Ketler, CEO for Vigmed, says “Our original ambitions to deliver the first products to the market before year end 2013, after a record short preparation phase, turned out to be too optimistic. Fine-tuning of the new assembly lines challenged our launch plans. We are fully aware of the fact that both our proposed distributors and users of Vigmed’s unique safety products are eagerly awaiting the market launch and we will do everything possible to ensure that there will be no further delay”.

*Vigmed is a Swedish medical technology company whose mission is to eliminate needlestick injuries by offering the market unique needle-protected products. Vigmed is headquartered in Helsingborg, Sweden, and has approximately 15 employees. Vigmed's share is traded on NASDAQ OMX First North in Stockholm (ticker VIG) and has approximately 5 400 shareholders. Remium Nordic AB is the Company's Certified Advisor. Additional information such as company description, a video presentation and risk factors can be found on Vigmed's home page: [www.vigmed.com/investor](http://www.vigmed.com/investor)*